Current Report Filing (8-k)
November 22 2016 - 2:41PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report: November 22, 2016
(Date of earliest event reported)
ENTEROMEDICS
INC.
(Exact name of registrant as specified in its charter)
Commission File Number: 1-33818
|
|
|
Delaware
|
|
48-1293684
|
(State or other jurisdiction
of incorporation)
|
|
(IRS Employer
Identification No.)
|
2800 Patton Road, St. Paul, Minnesota 55113
(Address of principal executive offices, including zip code)
(651) 634-3003
(Registrants telephone number, including area code)
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☒
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
On November 22, 2016, EnteroMedics Inc. (the Company) issued
a press release announcing that it will be hosting a conference call to discuss commercialization and corporate updates on Wednesday, November 30, 2016 at 11:00 AM Eastern Time ahead of the Companys anticipated special meeting of shareholders
to be held Monday, December 12, 2016 (the Special Meeting). Additionally, the press release urged all shareholders of record at the close of business of the Company on November 3, 2016 to vote FOR all of the management proposals at
the Special Meeting. A copy of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The full meeting agenda, including all of the management proposals is detailed in the Companys definitive proxy statement, which was
filed with the Securities and Exchange Commission (SEC) on November 17, 2016. The Company advises all investors and security holders to read the definitive proxy statement and other documents filed with the SEC carefully and in
their entirety. Investors and security holders may obtain free copies of the definitive proxy statement and other documents filed with the SEC by the Company through the web site maintained by the SEC at www.sec.gov. Free copies of the definitive
proxy statement and other documents filed with the SEC can also be obtained on the Companys website at http://ir.enteromedics.com/sec.cfm.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release dated November 22, 2016
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
ENTEROMEDICS INC.
|
|
|
By:
|
|
/s/ Scott Youngstrom
|
|
|
Scott Youngstrom
|
|
|
Chief Financial Officer and Chief Compliance Officer
|
Date: November 22, 2016
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release dated November 22, 2016
|
Enteromedics (NASDAQ:ETRM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enteromedics (NASDAQ:ETRM)
Historical Stock Chart
From Sep 2023 to Sep 2024